[1] Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma[J]. Ann Neurol, 2007, 61:25-36. [2] Dalmau J, Graus F. Autoimmune encephalitis:misdiagnosis, misconceptions, and how to avoid them[J]. JAMA Neurol, 2023, 80:12-14. [3] Braczkowski M, Soszyński D, Sierakowska A, Braczkowski R, Kufel K,Łabuz-Roszak B. Autoimmune encephalitis with antibodies:anti-NMDAR, anti-AMPAR, anti-GQ1b, anti-DPPX, anti-CASPR2, anti-LGI1, anti-RI, anti-Yo, anti-Hu, anti-CV2 and anti-GABAAR, in the course of psychoses, neoplastic diseases, and paraneoplastic syndromes[J]. Diagnostics (Basel), 2023, 13:2589. [4] Sakharova T, Aringazina R, Lilyanov N, Monov D. Features of the clinical course of autoimmune encephalitis associated with various antibodies[J]. Neurol Sci, 2024, 45:5413-5421. [5] Irani SR. Autoimmune encephalitis[J]. Continuum (Minneap Minn), 2024, 30:995-1020. [6] Gadoth A, Segal Y, Paran Y, Aizenstein O, Alcalay Y. The importance of tissue-based assay in the diagnosis of autoimmune encephalitis[J]. J Neurol, 2022, 269:3588-3596. [7] Masciocchi S, Businaro P, Scaranzin S, Morandi C, Franciotta D, Gastaldi M. General features, pathogenesis, and laboratory diagnostics of autoimmune encephalitis[J]. Crit Rev Clin Lab Sci, 2024, 61:45-69. [8] Endres D, Leypoldt F, Bechter K, Hasan A, Steiner J, Domschke K, Wandinger KP, Falkai P, Arolt V, Stich O, Rauer S, Prüss H, van Elst LT. Autoimmune encephalitis as a differential diagnosis of schizophreniform psychosis:clinical symptomatology, pathophysiology, diagnostic approach, and therapeutic considerations[J]. Eur Arch Psychiatry Clin Neurosci, 2020, 270:803-818. [9] Ancona C, Masenello V, Tinnirello M, Toscano LM, Leo A, La Piana C, Toldo I, Nosadini M, Sartori S. Autoimmune encephalitis and other neurological syndromes with rare neuronal surface antibodies in children:a systematic literature review[J]. Front Pediatr, 2022, 10:866074. [10] Fujita H, Shioda M, Suzuki K. Anti-LGI1 encephalitis recurring 3 years after the first episode:a case report[J]. BMC Neurol, 2022, 22:148. [11] de Bruijn MAAM, Leypoldt F, Dalmau J, Lee ST, Honnorat J, Clardy SL, Irani SR, Easton A, Kunchok A, Titulaer MJ. Autoimmune encephalitis[J]. Nat Rev Dis Primers, 2025, 11:65. [12] Freitas Henriques C, Fernandes R, Neves L, Miranda R, Noronha D, Aguiar TC, Faria T. Anti-LGI1 autoimmune limbic encephalitis:an easy-to-miss diagnosis[J]. Eur J Case Rep Intern Med, 2024, 11:005025. [13] Chao CH, Chu CC, Wei YC, Tseng JR, Chang HS. Anti-GABAB receptor encephalitis associated with combined small cell lung carcinoma[J]. J Neuroimmunol, 2021, 360:577705. [14] Kirschstein T, Köhling R. Functional changes in neuronal circuits due to antibody-driven autoimmune response[J]. Neurobiol Dis, 2023, 184:106221. [15] Gong S, Han Y, He E, Liu M, Fu X, Deng F. Coexistence of anti-SOX1 and anti-GABAB receptor antibodies with paraneoplastic limbic encephalitis presenting with seizures and memory impairment in small cell lung cancer:a case report[J]. Front Immunol, 2022, 13:955170. [16] Uchino A, Iizuka T, Urano Y, Arai M, Hara A, Hamada J, Hirose R, Dalmau J, Mochizuki H. Pseudo-piano playing motions and nocturnal hypoventilation in anti-NMDA receptor encephalitis:response to prompt tumor removal and immunotherapy[J]. Intern Med, 2011, 50:627-630. [17] Drekolias D, Gadela NV, Jacob J. Paraneoplastic confusion:a case of anti-Hu encephalitis[J]. Cureus, 2020, 12:e9205. [18] Benoliel T, Ben-Hur T, Vaknin-Dembinsky A. Autoimmune encephalitis:a bridge between neurology and psychiatry[J]. Harefuah, 2019, 158:361-366. [19] Sanvito F, Pichiecchio A, Paoletti M, Rebella G, Resaz M, Benedetti L, Massa F, Morbelli S, Caverzasi E, Asteggiano C, Businaro P, Masciocchi S, Castellan L, Franciotta D, Gastaldi M, Roccatagliata L. Autoimmune encephalitis:what the radiologist needs to know[J]. Neuroradiology, 2024, 66:653-675. [20] Son DK, Cho SM, Ryu HU, Shin BS, Kang HG. Anti-NMDAR encephalitis with bilateral basal ganglia MRI lesions at a distance of time:a case report[J]. BMC Neurol, 2022, 22:121. [21] Gupta D, Mehta A, Pradeep R, Javali M, Acharya PT, Srinivasa R. Faciobrachial dystonic seizures secondary to basal ganglia involvement in anti-LGI1 encephalitis[J]. Epileptic Disord, 2020, 22:517-518. [22] Chen Q, Ma Y, Li Z, Yu C, Wang X, Miao A. Distributions and network changes of brain activity in the acute phase of anti-NMDAR encephalitis:a MEG study[J]. J Neurol, 2025, 272:551. [23] Peer M, Prüss H, Ben-Dayan I, Paul F, Arzy S, Finke C. Functional connectivity of large-scale brain networks in patients with anti-NMDA receptor encephalitis:an observational study[J]. Lancet Psychiatry, 2017, 4:768-774. [24] Adams AV, Van Mater H, Gallentine W, Mooneyham GC. Psychiatric phenotypes of pediatric patients with seropositive autoimmune encephalitis[J]. Hosp Pediatr, 2021, 11:743-750. [25] Tebartz van Elst L, Runge K, Meyer PT, Urbach H, Venhoff N, Prüss H. The neuropsychiatric checklist for autoimmune psychosis:a narrative review[J]. Biol Psychiatry, 2025, 98:654-669. [26] Shi L, Liu S, Chen J, Wang H, Wang Z. Microglial polarization pathways and therapeutic drugs targeting activated microglia in traumatic brain injury[J]. Neural Regen Res, 2026, 21:39-56. [27] Cheng L, Jia B, Wang C, Fu Q, Zhou L. Immunotherapy for autoimmune encephalitis[J]. Cell Death Discov, 2025, 11:207. [28] Smets I, Titulaer MJ. Antibody therapies in autoimmune encephalitis[J]. Neurotherapeutics, 2022, 19:823-831. [29] Varley JA, Strippel C, Handel A, Irani SR. Autoimmune encephalitis:recent clinical and biological advances[J]. J Neurol, 2023, 270:4118-4131. [30] Nissen MS, Ryding M, Meyer M, Blaabjerg M. Autoimmune encephalitis:current knowledge on subtypes, disease mechanisms and treatment[J]. CNS Neurol Disord Drug Targets, 2020, 19:584-598. [31] Liu Y, Zhang Y, Song Z, Feng S, Cao T, Bu H. Treatment and prognosis of failure of first-line immunotherapy or recurrent autoimmune encephalitis patients with ofatumumab:a fully human anti-CD20 mAb[J]. Front Neurol, 2025, 16:1671481. [32] Shang H, Shen X, Yu X, Zhang J, Jia Y, Gao F. B-cell targeted therapies in autoimmune encephalitis:mechanisms, clinical applications, and therapeutic potential[J]. Front Immunol, 2024, 15:1368275. [33] Nosadini M, Thomas T, Eyre M, Anlar B, Armangue T, Benseler SM, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostásy K, Sakuma H, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK, Irani SR, Dalmau J, Lim M, Dale RC. International consensus recommendations for the treatment of pediatric NMDAR antibody encephalitis[J]. Neurol Neuroimmunol Neuroinflamm, 2021, 8:e1052. [34] Qin N, Wang J, Wu X, Wang W, Wang X, Peng X, Wang L. Characterization and prognosis of autoimmune encephalitis in the neurological intensive care unit:a retrospective study[J]. Neurol Sci, 2023, 44:2889-2895. [35] Berger B, Hauck S, Runge K, Tebartz van Elst L, Rauer S, Endres D. Therapy response in seronegative versus seropositive autoimmune encephalitis[J]. Front Immunol, 2023, 14:1196110. [36] Yang JH, Liu EN, Nguyen L, Dunn-Pirio A, Graves JS. Survival analysis of immunotherapy effects on relapse rate in pediatric and adult autoimmune encephalitis[J]. Neurology, 2023, 101:e2300-e2313. [37] Hermetter C, Fazekas F, Hochmeister S. Systematic review:syndromes, early diagnosis, and treatment in autoimmune encephalitis[J]. Front Neurol, 2018, 9:706. V, [38] Kim NN, Champsas D, Eyre M, Abdel-Mannan O, Lee Skippen A, Chitre MV, Forsyth R, Hemingway C, Kneen R, Lim M, Ram D, Ramdas S, Wassmer E, West S, Wright S, Biswas A, Mankad K, Flanagan EP, Palace J, Rossor T, Ciccarelli O, Hacohen Y. Pediatric MOG-Ab-associated encephalitis:supporting early recognition and treatment[J]. Neurol Neuroimmunol Neuroinflamm, 2024, 11:e200323. [39] Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, Christo PP, Dale RC, Fernandez-Fournier M, Flanagan EP, Gadoth A, George P, Grebenciucova E, Jammoul A, Lee ST, Li Y, Matiello M, Morse AM, Rae-Grant A, Rojas G, Rossman I, Schmitt S, Venkatesan A, Vernino S, Pittock SJ, Titulaer MJ; Autoimmune Encephalitis Alliance Clinicians Network. Autoimmune encephalitis:proposed best practice recommendations for diagnosis and acute management[J]. J Neurol Neurosurg Psychiatry, 2021, 92:757-768. [40] Körtvelyessy P, Prüss H, Thurner L, Maetzler W, Vittore-Welliong D, Schultze-Amberger J, Heinze HJ, Reinhold D, Leypoldt F, Schreiber S, Bittner D. Biomarkers of neurodegeneration in autoimmune-mediated encephalitis[J]. Front Neurol, 2018, 9:668. [41] Shim Y, Kim SY, Kim H, Hwang H, Chae JH, Choi J, Kim KJ, Yum MS, Ko TS, Kim YO, Byeon JH, Lee J, Lee J, Kim JS, Lim BC. Clinical outcomes of pediatric anti-NMDA receptor encephalitis[J]. Eur J Paediatr Neurol, 2020, 29:87-91. [42] Zheng J, Shen JF, Wang AP, Liu LJ, Xiong J, Li XF, Xiao YY, Li J, Mao DA, Liu LQ. Clinical characteristics of anti-N-methyl-D-aspartate receptor encephalitis in children[J]. Zhong Nan Da Xue Xue Bao (Yi Xue Ban), 2020, 45:47-54.[郑静,申金凤,汪爱平,刘玲娟,熊洁,李杏芳,肖阳阳,里健,毛定安,刘利群.儿童抗N-甲基-D-天冬氨酸受体脑炎的临床特征[J].中南大学学报(医学版), 2020, 45:47-54.] [43] Woo H, Shim Y, Chae JH, Kim KJ, Lim BC. Seizure evolution and outcome in pediatric autoimmune encephalitis[J]. Pediatr Neurol, 2023, 139:35-42. [44] Guang S, Ma J, Ren X, Zhou S, Yang J, Zhang J, Cao X, Zhong L, Ding X, Wang X, Ren C, Zhang W, Zhang L, Zhang M, Sun J, Kessi M, Yin F, Peng J, Jiang Y. Immunotherapies for anti-N-M-methyl-D-aspartate receptor encephalitis:multicenter retrospective pediatric cohort study in China[J]. Front Pediatr, 2021, 9:691599. [45] Wright MA, Trandafir CC, Nelson GR, Hersh AO, Inman CJ, Zielinski BA. Diagnosis and management of suspected pediatric autoimmune encephalitis:a comprehensive, multidisciplinary approach and review of literature[J]. J Child Neurol, 2022, 37:303-313. [46] Vova JA, Howarth RA. Evaluation, treatment, and outcomes of viral and autoimmune encephalitis in children[J]. Pediatr Clin North Am, 2023, 70:429-444. [47] Cellucci T, Van Mater H, Graus F, Muscal E, Gallentine W, Klein-Gitelman MS, Benseler SM, Frankovich J, Gorman MP, Van Haren K, Dalmau J, Dale RC. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient[J]. Neurol Neuroimmunol Neuroinflamm, 2020, 7:e663. [48] Mojžišová H, Krýsl D, Hanzalová J, Dargvainiene J, Wandinger KP, Leypoldt F, Elišák M, Marusič P. Antibody-negative autoimmune encephalitis:a single-center retrospective analysis[J]. Neurol Neuroimmunol Neuroinflamm, 2023, 10:e200170. [49] Blaabjerg M, Seifert-Held T, Sellner J. Editorial:emerging challenges in the diagnosis and treatment of autoimmune encephalitis[J]. Front Neurol, 2019, 10:146. [50] Abboud H, Clardy SL, Dubey D, Wickel J, Day GS, Geis C, Gelfand JM, Irani SR, Lee ST, Titulaer MJ. The clinical trial landscape in autoimmune encephalitis:challenges and opportunities[J]. Neurology, 2025, 104:e213487. autoimmune [51] Dalmau J, Graus F. Diagnostic criteria for encephalitis:utility and pitfalls for antibody-negative disease[J]. Lancet Neurol, 2023, 22:529-540. [52] Li LY, Keles A, Homeyer MA, Prüss H. Antibodies in neurological diseases:established, emerging, explorative[J]. Immunol Rev, 2024, 328:283-299. [53] Budhram A, Dubey D, Sechi E, Flanagan EP, Yang L, Bhayana V, McKeon A, Pittock SJ, Mills JR. Neural antibody testing in patients with suspected autoimmune encephalitis[J]. Clin Chem, 2020, 66:1496-1509. Jalali-Yazdi F, Okada NJ, [54] Jones BE, Tovar KR, Goehring A, Gouaux E, Westbrook GL. Autoimmune receptor encephalitis in mice induced by active immunization with conformationally stabilized holoreceptors[J]. Sci Transl Med, 2019, 11:eaaw0044. [55] Schwenkenbecher P, Skripuletz T, Lange P, Dürr M, Konen FF, Möhn N, Ringelstein M, Menge T, Friese MA, Melzer N, Malter MP, Häusler M, Thaler FS, Stangel M, Lewerenz J, Sühs KW; German Network for Research on Autoimmune Encephalitis. Intrathecal antibody production against Epstein-Barr, herpes simplex, and other neurotropic viruses in autoimmune encephalitis[J]. Neurol Neuroimmunol Neuroinflamm, 2021, 8:e1062. [56] Madani J, Yea C, Mahjoub A, Brna P, Jones K, Longoni G, Nouri MN, Rizk T, Stewart WA, Wilbur C, Yeh EA. Clinical features and outcomes in children with seronegative autoimmune encephalitis[J]. Dev Med Child Neurol, 2024, 66:1310-1318. [57] Lee S, Kim HD, Lee JS, Kang HC, Kim SH. Clinical features and treatment outcomes of seronegative pediatric autoimmune encephalitis[J]. J Clin Neurol, 2021, 17:300-306. [58] Wang Y, Zhang D, Tong L, Yang L, Yin P, Li J, Lei G, Yang X, Li B. Anti-LGI1 encephalitis with initiating symptom of seizures in children[J]. Front Neurosci, 2023, 17:1151430. [59] Chen L, Su T, Liu Y. Clinical characteristics of leucine-rich glioma-inactivated protein 1 antibody-mediated autoimmune encephalitis in a 6-year-old girl:case report and literature reviews[J]. BMC Neurol, 2023, 23:253. [60] Jang S, Kim SY, Kim WJ, Chae JH, Kim KJ, Lim BC. A case of pediatric anti-leucine-rich glioma inactivated 1 encephalitis with faciobrachial dystonic seizure[J]. Brain Dev, 2023, 45:348-353. [61] Vaisvilas M, Petrosian D, Bagdonaite L, Taluntiene V, Kralikiene V, Daugelaviciene N, Neniskyte U, Kaubrys G, Giedraitiene N. Seroprevalence of neuronal antibodies in diseases mimicking autoimmune encephalitis[J]. Sci Rep, 2024, 14:5352. [62] Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, Blackburn KM, Turaga S, Binks S, Zitser J, Gelfand JM, Day GS, Dunham SR, Rodenbeck SJ, Clardy SL, Solomon AJ, Pittock SJ, McKeon A, Dubey D, Zekeridou A, Toledano M, Turner LE, Vernino S, Irani SR. Autoimmune encephalitis misdiagnosis in adults[J]. JAMA Neurol, 2023, 80:30-39. [63] Van Steenhoven RW, de Vries JM, Bruijstens AL, Paunovic M, Nagtzaam MM, Franken SC, Bastiaansen AE, De Bruijn MA, Van Sonderen A, Schreurs MWJ, Gardeniers M, Verdijk RM, Balvers RK, Sillevis Smitt PA, Neuteboom RF, Titulaer MJ. Mimics of autoimmune encephalitis:validation of the 2016 clinical autoimmune encephalitis criteria[J]. Neurol Neuroimmunol Neuroinflamm, 2023, 10:e200148. [64] Day GS. Rapidly progressive dementia[J]. Continuum (Minneap Minn), 2022, 28:901-936. [65] Hoshina Y, Smith TL, Mstat AD, Wong KH, Peterson LK, Zekeridou A, Aboseif A, Coffey C, Wright MA, Banwell B, Dialino-Felix A, Flavin S, Dill L, Titulaer MJ, Day GS, Clardy SL. An updated, comprehensive meta-analysis of the treatment of anti-NMDAR encephalitis:analysis, equipoise, and the urgent need for evidence over anecdote[J]. J Neuroimmunol, 2025, 405:578651. [66] Seery N, Wesselingh R, Beech P, McLaughlin LM, Rushen T, Halliday AJ, Horst LT, Griffith SP, Forcadela M, Tan TH, Kazzi C, Nesbitt C, Broadley J, Buzzard K, Duncan AJ, D'Souza WJ, Tran YD, Van Der Walt A, Skinner G, Taylor BV, Swayne A, Brodtmann A, Gillis D, Butler EG, Kalincik T, Seneviratne UK, Macdonell RA, Blum S, Ramanathan S, Malpas CB, Reddel SW, Hardy TA, O'Brien TJ, Sanfilippo PG, Butzkueven H, Monif M; Australian Autoimmune Encephalitis Consortium. Acute and long-term immune-treatment strategies in anti-LGI1 antibody-mediated encephalitis:a multicenter cohort study[J]. Neurol Neuroimmunol Neuroinflamm, 2025, 12:e200412. [67] Cannon L, Pan A, Kovalick L, Sarkissian A, Wu EY. Secondary immunodeficiencies and infectious considerations of biologic immunomodulatory therapies[J]. Ann Allergy Asthma Immunol, 2023, 130:718-726. [68] Pollak TA, Vincent A, Iyegbe C, Coutinho E, Jacobson L, Rujescu D, Stone J, Jezequel J, Rogemond V, Jamain S, Groc L, David A, Egerton A, Kahn RS, Honnorat J, Dazzan P, Leboyer M, McGuire P. Relationship between serum NMDA receptor antibodies and response to antipsychotic treatment in first-episode psychosis[J]. Biol Psychiatry, 2021, 90:9-15. [69] Hauptman AJ, Ferrafiat V. Neuroinflammatory syndromes in children[J]. Curr Opin Psychiatry, 2023, 36:87-95. [70] Nguyen L, Yang JH, Goyal S, Irani N, Graves JS. A systematic review and quantitative synthesis of the long-term psychiatric sequelae of pediatric autoimmune encephalitis[J]. J Affect Disord, 2022, 308:449-457. [71] Mazowiecki M, Flet-Berliac L, Roux J, Lépine A, Chretien P, Hacein-Bey-Abina S, Giorgi L, Villega F, Cheuret E, Benaiteau M, Rogemond V, Picard G, Baer S, Cleuziou P, Lametery E, Desguerre I, Aubart M, Chevignard M, Le Grand R, Horellou P, Leroy C, Joubert B, Honnorat J, Deiva K. Long-term clinical and biological prognostic factors of anti-NMDA receptor encephalitis in children[J]. Neurol Neuroimmunol Neuroinflamm, 2025, 12:e200346. [72] Bhasin A, Haftka-George A. Diagnostic challenges and treatment approach to seronegative autoimmune encephalitis[J]. Cureus, 2024, 16:e56844. [73] Lee WJ, Lee ST, Shin YW, Lee HS, Shin HR, Kim DY, Kim S, Lim JA, Moon J, Park KI, Kim HS, Chu K, Lee SK. Teratoma removal, steroid, IVIG, rituximab and tocilizumab (T-SIRT) in anti-NMDAR encephalitis[J]. Neurotherapeutics, 2021, 18:474-487. [74] Dinoto A, Cheli M, Bratina A, Sartori A, Manganotti P. Bortezomib in anti-N-Methyl-D-Aspartate-Receptor (NMDA-R) encephalitis:a systematic review[J]. J Neuroimmunol, 2021, 356:577586. [75] Xu B, Bai Y, Liu Z, Li J, Chen K, Zi Y, Wang Y, Xu J, Wang H, Shi FD, Wang J, Wang H. Harnessing patient-derived antibodies-induced microglial complement 1q expression:novel therapy for anti-NMDAR encephalitis[J]. Mol Ther, 2025, 33:5721-5740. [76] Vieira GD, Boldrini VO, Mader S, Kümpfel T, Meinl E, Damasceno A. Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders[J]. Mult Scler Relat Disord, 2025, 95:106311. [77] Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics[J]. Nat Rev Neurol, 2020, 16:601-617. [78] Homeyer MA, Falck A, Li LY, Prüss H. From immunobiology to intervention:pathophysiology of autoimmune encephalitis[J]. Semin Immunol, 2025, 78:101955. [79] Zrzavy T, Endmayr V, Bauer J, Macher S, Mossaheb N, Schwaiger C, Ricken G, Winklehner M, Glatter S, Breu M, Wimmer I, Kovacs GG, Risser DU, Klupp N, Simonitsch-Klupp I, Roetzer T, Rommer P, Berger T, Gelpi E, Lassmann H, Graus F, Dalmau J, Höftberger R. Neuropathological variability within a spectrum of NMDAR-encephalitis[J]. Ann Neurol, 2021, 90:725-737. [80] Datta AK, Pandit A, Biswas S, Biswas A, Roy BK, Gangopaddhyay G. Spectrum of anti-NMDA receptor antibody encephalitis:clinical profile, management and outcomes[J]. Ann Indian Acad Neurol, 2021, 24:383-389. [81] Krohn S, Müller-Jensen L, Kuchling J, Romanello A, Wurdack K, Rekers S, Bartsch T, Leypoldt F, Paul F, Ploner CJ, Prüss H, Finke C. Cognitive deficits in anti-LGI1 encephalitis are linked to immunotherapy-resistant white matter network changes[J]. Neurol Neuroimmunol Neuroinflamm, 2025, 12:e200360. [82] Hechler A, Kuchling J, Müller-Jensen L, Klag J, Paul F, Prüss H, Finke C. Hippocampal hub failure is linked to long-term memory impairment in anti-NMDA-receptor encephalitis:insights from structural connectome graph theoretical network analysis[J]. J Neurol, 2024, 271:5886-5898. [83] Kuchling J, Jurek B, Kents M, Kreye J, Geis C, Wickel J, Mueller S, Koch SP, Boehm-Sturm P, Prüss H, Finke C. Impaired functional connectivity of the hippocampus in translational murine models of NMDA-receptor antibody associated neuropsychiatric pathology[J]. Mol Psychiatry, 2024, 29:85-96. [84] Yang Y, Fu S, Jiang G, Xu G, Tian J, Ma X. Functional connectivity changes of the hippocampal subregions in anti-N-methyl-D-aspartate receptor encephalitis[J]. Brain Imaging Behav, 2024, 18:686-697. [85] Li G, Liu X, Yu T, Ren J, Wang Q. Positron emission tomography in autoimmune encephalitis:clinical implications and future directions[J]. Acta Neurol Scand, 2022, 146:708-715. [86] Hartung TJ, Bartels F, Kuchling J, Krohn S, Leidel J, Mantwill M, Wurdack K, Yogeshwar S, Scheel M, Finke C. MRI findings in autoimmune encephalitis[J]. Rev Neurol (Paris), 2024, 180:895-907. [87] Sapana T, Li W, Tian F, Yan W, Dou B, Hua S, Zhuo Z. A case report of anti-GAD65 antibody-positive autoimmune encephalitis in children associated with autoimmune polyendocrine syndrome type-Ⅱ and literature review[J]. Front Immunol, 2023, 14:1274672. [88] Aboseif A, Toljan K, Mahadeen A, Zeft A, Moosa AN, Pestana-Knight E, Abrams A. Pediatric anti-NMDA-receptor autoimmune encephalitis in siblings:developmental, electrophysiologic, and genetic implications[J]. J Neuroimmunol, 2023, 379:578107. [89] Doden T, Sekijima Y, Ikeda J, Ozawa K, Ohashi N, Kodaira M, Hineno A, Tachibana N, Ikeda SI. Postpartum anti-N-methyl-D-aspartate receptor encephalitis:a case report and literature review[J]. Intern Med, 2017, 56:357-362. [90] Karagianni P, Alexopoulos H, Sourdi A, Papadimitriou D, Dimitrakopoulos AN, Moutsopoulos HM. West Nile Virus infection triggering autoimmune encephalitis:pathophysiological and therapeutic implications[J]. Clin Immunol, 2019, 207:97-99. [91] Huang EY, Gao H, Zhong N. Heterogeneity of clinical features, EEG and brain imaging findings in anti-leucine-rich glioma-inactivated protein 1 autoimmune encephalitis:a retrospective case series study and review of the literature[J]. Acta Epileptol, 2023, 5:21. [92] Wang Y, Zhou Q, Dai Z, Qiu Y, Zhou H, Feng L, Zhao J. Clinical and brain MRI characteristics of patients with anti-N-methyl-D-aspartate receptor encephalitis:a 10-year retrospective study[J]. Eur Neurol, 2025, 88:71-81. [93] Fan B, Wu P, Zhou X, Chen Z, Pang L, Shi K, Zheng J. Aberrant resting-state interhemispheric functional connectivity in patients with anti-N-methyl-D-aspartate receptor encephalitis[J]. Neuroradiology, 2022, 64:2021-2030. [94] Meeker KL, Butt OH, Gordon BA, Fagan AM, Schindler SE, Morris JC, Benzinger TLS, Ances BM. Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage[J]. Neurobiol Dis, 2022, 166:105662. [95] Aboseif A, Mangioris G, Yang B, Pazdernik VK, Britton JW, Dubey D, Flanagan EP, Irani SR, Day GS, Howe CL, López-Chiriboga AS, McKeon A, Mills JR, Segal Y, Toledano M, Vodopivec I, Pittock SJ, Zekeridou A. Cytokine, chemokine, and neurofilament light chain signatures in LGI1 autoimmune encephalitis[J]. Ann Clin Transl Neurol, 2025, 12:2258-2270. [96] Chang H, Ma J, Feng K, Feng N, Wang X, Sun J, Guo T, Wei Y, Xu Y, Wang H, Yin L, Zhang X. Elevated blood and cerebrospinal fluid biomarkers of microglial activation and blood-brain barrier disruption in anti-NMDA receptor encephalitis[J]. J Neuroinflammation, 2023, 20:172. [97] Ma Y, Wang J, Guo S, Meng Z, Ren Y, Xie Y, Wang M. Cytokine/chemokine levels in the CSF and serum of anti-NMDAR encephalitis:a systematic review and meta-analysis[J]. Front Immunol, 2023, 13:1064007. [98] Muñoz-Sánchez G, Guasp M, Muñoz-Lopetegi A, Luchoro JF, Martínez-Hernández E, Naranjo L, Erro ME, Martín-Aguilar L, Iizuka T, Simabukuro MM, Romera MA, Couso RS, Sabater L, Saiz A, Graus F, Dalmau JO, Ruiz-García R; Anti-LGI1 Encephalitis Study Group. Cytokine and chemokine profiles in anti-LGI1 encephalitis:markers of severity and outcome[J]. Neurol Neuroimmunol Neuroinflamm, 2025, 12:e200492. [99] Dorcet G, Benaiteau M, Pariente J, Ory-Magne F, Cheuret E, Rafiq M, Brooks W, Puissant-Lubrano B, Fortenfant F, Renaudineau Y, Bost C. Cerebrospinal fluid YKL-40 level evolution is associated with autoimmune encephalitis remission[J]. Clin Transl Immunology, 2023, 12:e1439. |